PTPN21

Across TCGA pan-cancer cohorts, PTPN21 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PTPN21 data layer compared with 22 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PTPN21 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PTPN21 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

LUAD, PDAC, and GBM are the cancer types where PTPN21 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	All	0.849	1.000	.002	28	view →
PDAC	DFS	Median	II,III,IV	0.583	0.793	.005	23	view →
GBM	OS	Tertile	All	0.922	0.803	.010	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

PTPN21–LUAD (DFS)

Open the LUAD breakdown →